Get the Stockscreener App
2.4626
4.74%
-0.0674
Ernexa Therapeutics Inc stock is traded at $2.4626, with a volume of 39,834.
It is down -4.74% in the last 24 hours and down -28.27% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$2.53
Open:
$2.52
24h Volume:
39,834
Relative Volume:
1.32
Market Cap:
$1.16M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.2963
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
+1.37%
1M Performance:
-28.27%
6M Performance:
-40.49%
1Y Performance:
-91.73%
1-Day Range:
$2.43
$2.60
1-Week Range:
$2.08
$2.7493
52-Week Range:
$2.08
$39.38
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
2.4796 | 1.16M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.44 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.17 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.69 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.94 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Ernexa Therapeutics (NASDAQ:ERNA) Shares Up 5.9% – What’s Next? - Defense World
Sector Update: Health Care - marketscreener.com
Ernexa Therapeutics Shares Fall Pre-Bell Following Reverse Stock Split - marketscreener.com
Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split - MSN
Ernexa Therapeutics announces 1-for-15 reverse stock split By Investing.com - Investing.com South Africa
Eterna Therapeutics Implements 1-for-15 Reverse Stock Split - TipRanks
Ernexa Therapeutics announces 1-for-15 reverse stock split - Investing.com
Ernexa Therapeutics registers 57M shares for resale - MSN
Ernexa therapeutics ten percent owner acquires $2.22 million in stock By Investing.com - Investing.com Nigeria
Ernexa therapeutics ten percent owner acquires $2.22 million in stock - Investing.com Australia
Eterna Therapeutics Files for Resale of 57 Million Shares - marketscreener.com
Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance - Nasdaq
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split - citybiz
Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish - MSN
Ernexa Therapeutics Announces 1-For-15 Reverse Stock Split - marketscreener.com
Ernexa Plans 93% Share Reduction in Critical Nasdaq Compliance Move - Stock Titan
Eterna Therapeutics Completes $6M Private Placement - TipRanks
Eterna Therapeutics Increases Authorized Shares and Amends Bylaws - TipRanks
Ernexa Therapeutics announces new data to be presented at ASCO meeting 2025 - TipRanks
Ernexa Therapeutics to Present Breakthrough Data on iMSC-Based Immunotherapy at ASCO Annual Meeting 2025 - Nasdaq
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 - GlobeNewswire
Ernexa Therapeutics Establishes Texas Subsidiary to Support - GlobeNewswire
Ernexa's New Texas Hub Accelerates Novel Ovarian Cancer Treatment: MD Anderson Expert Leads Research - Stock Titan
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
ERNAErnexa Latest Stock News & Market Updates - Stock Titan
Can Ernexa Crack Ovarian Cancer with Novel Stem Cell Approach? - Inside Precision Medicine
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire
Revolutionary Stem Cell Therapy Fights Cancer in Two Ways, MD Anderson Study Shows - Stock Titan
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times
Revolutionary Tumor-Fighting Cell Therapy: MD Anderson to Present Ernexa's Ovarian Cancer Breakthrough at AACR - Stock Titan
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com
Smart Trial Design In Cell Therapy: Fast-Tracking Without Compromising - Clinical Leader
Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia
ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India
Ernexa Therapeutics Closes New Funding Round - GlobeNewswire
Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ernexa Therapeutics Inc Stock (ERNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Apr 02 '25 |
Buy |
0.10 |
3,768,397 |
394,174 |
20,401,602 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):